Artritter

Van Venrooij WJ, van Beers JBC, Pruij GJM. Anti-CCP antibody, a marker for the early detection of rheumatoid arthritis. Ann NY Acad Sci 2008;1143:268-285

Van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis. Arthritis Rheum 2004;50:709-15

Kiely PDW, Brown AK, Edwards CJ, et al. Contemporary treatment principles for early rheumatoid arthritis: a consensus statement. Rheumatology 2009;48:765-72

Smolen JS, Aletaha D, Bijlsma JWJ et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-637

Flatø B, Vinje O. Epidemiologien ved juvenil idiopatisk artritt og andre artritter i barnealderen. Norsk epidemiologi 2008;18:93-8

Eilertsen GØ, Becker-Merok A, Nossent JC. The influence of the 1997 updated classification criteria for systemic lupus erythematosus: epidemiology, disease presentation, and patient management. J Rheumatol 2009;36:552-9

Bertsias G, Ioannidis JPA, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Reports of a task force of the EULAR standing committee for international clinical studies including therapeutics. Ann Rheum Dis 2008;67:195-205

Brun JG, Jonsson R. Sjögrens syndrom. Norsk epidemiologi 2008; 18 (1): 67-72

Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American European Consensus Group. Ann Rheum Dis 2002;61:554-8

Kowal-Bielecka O, Landewe R, Avouac J et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR scleroderma trials and research group (EUSTAR). Ann Rheum Dis 2009;68:620-8

Chakravarty K, Elgabani SH, Scott DG, Merry P. A district audit on the management of polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 1994;33:152-6

Salvarini C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008;372:234-45

Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009;68:318-23

Zhang W, Doherty M, Bardin T et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24

Pascual E, Sivera F. Therapeutic advanced in gout. Curr Opin Rheumatol 2007;19:122-7

Hannu T, Mattila L, Siitonen A, Leirisalo-Repo M. Reactive arthritis attributable to Shigella infection: a clinical and epidemiological nationwide study. Ann Rheum Dis 2005;64:594-598

Townes JM. Reactive Arthritis after Enteric Infections in the United States: The Problem of Definition. Clinical Infectious Diseases 2010;50:247-54

Watts RA, Scott DGI. Recent developements in the classification and assessment of vasculitis. Best Practice&Research Clinical Rheumatology 2009;23:429-43

Pagnoux C et al. Clinical Features and Outcomes in 348 Patients with Polyartheritis Nodosa. Arthritis Rheum 2010;62:616-26

Artrose

Slatkowsky-Christensen B, Grotle M. Artrose i Norge. Norsk epidemiologi 2008;18:99-106

Bijlsma JWJ, Lafeber FPJG. Glucosamine sulfate in osteoarthritis. The jury is still out. Editorial. Ann Intern Med 2008;148:315-6

Jordan KM et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-55

Degenerative leddsykdommer

Norsk fysikalsk medisin, 2. utg. Red: Niels Gunnar Juel. Fagbokforlaget 2007

EULAR evidence-based recommendations for the management of fibromyalgia syndrome. S F Carville et al. Ann Rheum Dis 2008;67:536–541.

Osteoporose

Pazianas M, Epstein S, Zaidi M. Evaluating the antifracture efficacy of biphosphonates. Rev Recent Clin Trials 2009;4:122-130

Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822

Lyles KW, Colon-Emeric CS, Magaziner JS et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357: 1799-1809

Grey A, Bolland MJ, Wattie D, Horne A, Gamble G, Reid IR. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebocontrolled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab 2009; 94: 538-544

Hadji P. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 2009; 69: 73-82

Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008; 9: 840-849

Hershman DL, McMahon DJ, Crew KD et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008; 26: 4739-4745

Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360: 679-691

Cosman F. Parathyroid hormone treatment for osteoporosis. Curr Opin Endocrinol Diabetes Obes 2008; 15: 495-501

Obermayer-Pietsch BM, Marin F, McCloskey EV et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 2008; 23: 1591-1600

Eastell R, Nickelsen T, Marin F et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 2009; 24: 726-736

Finkelstein JS, Leder BZ, Burnett SM et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 2006; 91: 2882-2887

Saag KG, Shane E, Boonen S et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357: 2028-2039